Nipocalimab Market Size Forecast and Emerging Insights Signal Strong Growth Outlook Through 2034, estimates DelveInsight

According to DelveInsight’s latest analysis, Nipocalimab is expected to capture meaningful market share across both prevalent ...

'The answer cannot be nothing': The battle over Canada's mystery brain disease

A small Canadian province feared it had a mystery neurological illness on its hands. The search for answers set off a battle ...
pharmaphorum

Expanding the haematology toolkit: Insights and operational imperatives from ASH 2025

The 2025 American Society of Hematology (ASH) meeting in December presented a clear message: scientific innovation and ...

The battle over Canada's mystery brain disease

A small Canadian province feared it had a mystery neurological illness on its hands. The search for answers set off a battle ...
BioWorld

Hutchmed plans China NDA filing of sovleplenib in rare anemia

Hutchmed Ltd. plans to file a second NDA in China for sovleplenib, a novel spleen tyrosine kinase inhibitor, based on positive phase II/III findings in warm antibody autoimmune hemolytic anemia.